Deepmala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Deepmala has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Charles Spielholz
BioAdvantex Pharma Inc., MaRS Discovery District, Toronto, ON, Canada
1 shared publicationJohn Slattery
Arkansas Children's Hospital, Little Rock, AR, United States; Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, United States
1 shared publicationLeanna Delhey
Arkansas Children's Hospital, Little Rock, AR, United States; Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, United States
1 shared publicationMayank Agrawal
University of Arkansas for Medical Sciences, Little Rock, AR, USA
1 shared publication- Michael Berk
Barwon Health
1 shared publication Nihit Kumar
Arkansas Children's Hospital, Little Rock, AR, United States; Department of Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, United States
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 1 August 2015
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 55, 294-321
Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
- 1 August 2015
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 55, 294-321
Top Cited PapersOpen AccessClinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
- Open Access
- 25 June 2014
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 48 (10) , 1385-1388
Use of Propranolol for Hypersexual Behavior in an Adolescent With Autism
Objective: To report a case of an adolescent with autism with clinically significant hypersexual behaviors in whom a trial of low-dose propranolol led to major clinical improvement. Case Summary: This case report describes a 13-year-old boy with a history of autism who presented to the outpatient psychiatric clinic for hypersexual behaviors that started at the onset of puberty. The behaviors affected his functioning both at school and home. A trial of low-dose propranolol, 0.3 mg/kg/d (10 mg twice a day), targeting hypersexual behavior led to remarkable clinical improvement. The behaviors remained stable on this dose of propranolol for 1 year. Discussion: Hypersexual behavior exhibited by adolescent patients with autism can be a big challenge to manage. The literature on pharmacological options to manage these behaviors in children and adolescents with autism is limited. Clinical data of propranolol use are novel. Conclusion: To our knowledge, this is the first case report of low-dose propranolol leading to clinically significant improvement in hypersexual behaviors in an adolescent with autism. Propranolol use may expand the choice of treatment option in this patient population.
- 25 June 2014
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 48 (10) , 1385-1388
Open AccessUse of Propranolol for Hypersexual Behavior in an Adolescent With Autism
Objective: To report a case of an adolescent with autism with clinically significant hypersexual behaviors in whom a trial of low-dose propranolol led to major clinical improvement. Case Summary: This case report describes a 13-year-old boy with a history of autism who presented to the outpatient psychiatric clinic for hypersexual behaviors that started at the onset of puberty. The behaviors affected his functioning both at school and home. A trial of low-dose propranolol, 0.3 mg/kg/d (10 mg twice a day), targeting hypersexual behavior led to remarkable clinical improvement. The behaviors remained stable on this dose of propranolol for 1 year. Discussion: Hypersexual behavior exhibited by adolescent patients with autism can be a big challenge to manage. The literature on pharmacological options to manage these behaviors in children and adolescents with autism is limited. Clinical data of propranolol use are novel. Conclusion: To our knowledge, this is the first case report of low-dose propranolol leading to clinically significant improvement in hypersexual behaviors in an adolescent with autism. Propranolol use may expand the choice of treatment option in this patient population.